Starting Long-Acting Inhaled Bronchodilators Tied To The Risk Of Heart Attack
A Taiwanese nested case-control study shows 50 percent of (1.5 fold) enhanced risk of cardiovascular diseases among patients with a chronic obstructive pulmonary disease (COPD) within first 30 days with the use of long-acting inhaled bronchodilators when compared with the non-users. The enhanced risk is irrespective of the patient's history of exacerbations and the previous cardiovascular disease.
But the absolute risk of cardiovascular disease with long-acting inhaled bronchodilators was still around one percent among patients with chronic obstructive pulmonary disease (COPD). But the enhanced risk of cardiovascular disease will die over a period.
A two-year follow-up study was done on the use of COPD on 284,220 patients from the Taiwan National Health Insurance Research Database, aged at least 40 years with an average age of 71.4 years at the start of the study. The percentage of the women participants was 31.1. The study participants were never users of long-acting inhaled bronchodilators for the treatment of COPD, prior to the start of the study. They are taking long-acting bronchodilators, either beta agonists (LABAs) or antimuscarinic antagonists (LAMAs) for the first time.
The study shows the development of severe heart problems such as arrhythmia, heart failure, coronary artery disease or ischemic stroke and the need for emergency medical care in 37,719 patients with COPD. The average age of the patients was 75.6 years. About 71.6 percent of them were men.
The study also shows there was no difference in the risk of cardiovascular disease with either beta agonists or antimuscarinic antagonists or with the dosage.
The use of long-acting inhaled bronchodilators is essential for the treatment of COPD. Long-acting inhaled bronchodilators are designed to enlarge the airways in the lungs. These drugs can lower the severity of the disease and can improve the lung function. But they cause an inflammation and affect the cardiovascular health by increasing the blood pressure and heartbeat, narrowing of blood vessels and the formation of blockages in blood vessels.
The patients with chronic obstructive pulmonary disease (COPD) should know the immediate risk of cardiovascular disease when they start with inhaled long-acting bronchodilators. A patient with COPD should pay attention to the symptoms of heart disease such as arrhythmias (palpitations, irregular heartbeat), difficulty in breathing or chest pain. The patient should undergo a regular check-up with a specialist for a possible risk of cardiovascular disease after starting the inhalers. If the inhaled bronchodilators are prescribed by the doctor, the patient with a chronic obstructive pulmonary disease (COPD) should not avoid it.
The lead author of the study was Dr. Meng-Ting Wang, Ph.D., an Assistant Professor, School of Pharmacy, National Defense Medical Center, Taipei, Taiwan. The study was published January 2, 2018, in the JAMA Internal Medicine. Title of the article was "Association of Cardiovascular Risk With Inhaled long-acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease. A Nested Case-Control Study."
COPD: Chronic obstructive pulmonary disease (COPD) is a progressive lung disease affecting people aged more than 40 years. It is the third leading cause of death in the United States. This disease is caused due to the blockage of the air flow to the lungs. It lasts for years as the damage to the lungs due to disease cannot be reversed. A treatment can reduce disease symptoms, but the disease cannot be cured. Symptoms of COPD are.
Smoking is the main cause of COPD. It can also be due to the prolonged exposure to the irritating substances or gases. The worsening of COPD can be prevented by reducing smoking and improving the air quality. If left untreated, COPD will increase the risk of heart diseases, lung cancer and respiratory infections.
Chronic obstructive pulmonary disease: Please see COPD.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.